(vianews) - shares of gensight biologics (cac 40: sight.pa) slid by a staggering 20.39% to €2.46 at 10:54 est on tuesday, following the last session's downward trend. cac 40 is rising 0.16% to €7,385.26, after two consecutive sessions in a row of gains. this seems, so far, a somewhat positive trend trading session today.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. gensight biologics s.a. was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.968.
volume
today's last reported volume for gensight biologics is 682904 which is 819.89% above its average volume of 74237.
more news about gensight biologics (sight.pa).